scholarly journals Multiple Sclerosis and Celiac Disease

10.5772/47882 ◽  
2012 ◽  
Author(s):  
Carlos Hernndez-Lahoz ◽  
Luis Rodrigo
Keyword(s):  
Multiple Sclerosis ◽  
Celiac Disease

scholarly journals IL23R: a susceptibility locus for celiac disease and multiple sclerosis?

2008 ◽  
Vol 9 (4) ◽  
pp. 289-293 ◽  
Author(s):  
C Núñez ◽  
B Dema ◽  
M C Cénit ◽  
I Polanco ◽  
C Maluenda ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Celiac Disease ◽  
Susceptibility Locus

Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease

2008 ◽  
Vol 69 (12) ◽  
pp. 837-839 ◽  
Author(s):  
Giovanni Frisullo ◽  
Viviana Nociti ◽  
Raffaele Iorio ◽  
Agata Katia Patanella ◽  
Alessandro Marti ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Celiac Disease ◽  
B Cells

Celiac disease, Behçet, and idiopathic thrombocytopenic purpura in siblings of a patient with multiple sclerosis

2009 ◽  
Vol 15 (11) ◽  
pp. 1368-1371 ◽  
Author(s):  
Bassem Yamout ◽  
Jinan Usta ◽  
Salam Itani ◽  
Shadi Yaghi
Keyword(s):  
Multiple Sclerosis ◽  
Celiac Disease ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Demyelinating Disease ◽  
Human Leukocyte ◽  
Epstein Barr Virus Infection ◽  
Thrombocytopenic Purpura ◽  
Barr Virus ◽  
Epstein Barr ◽  
Barr Virus Infection

Multiple sclerosis (MS) is a demyelinating disease of uncertain etiology. Many genetic and environmental risk factors have been associated with this disease including certain human leukocyte antigen haplotypes, Epstein-Barr virus infection, and vitamin D deficiency. We report a 30-year-old woman with MS, the product of consanguineous marriage, and three siblings with three different autoimmune diseases: idiopathic thrombocytopenic purpura, celiac disease, and Behçet’s disease.

Association of Multiple Sclerosis and Celiac Disease: Case Report

2011 ◽  
Vol 31 (1) ◽  
pp. 240-244
Author(s):  
İrem Fatma ULUDAĞ ◽  
Uğur KULU ◽  
Ufuk ŞENER ◽  
Yaşar ZORLU ◽  
Işın GÖKÇÖL ERDOĞAN
Keyword(s):  
Multiple Sclerosis ◽  
Celiac Disease ◽  
Case Report ◽  
Disease Case

Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis

2020 ◽  
Vol 26 (13) ◽  
pp. 1801-1803 ◽  
Author(s):  
Maksim Son ◽  
Lynn McEwan ◽  
Manaf Ubaidat ◽  
Keith Bovell ◽  
Sarah A Morrow
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Event ◽  
Celiac Disease ◽  
Genetic Testing ◽  
Gastrointestinal Symptoms ◽  
Lymphocytic Colitis ◽  
Gastrointestinal Adverse Event ◽  
Severe Diarrhea ◽  
Endomysial Antibodies ◽  
Relapsing Multiple Sclerosis

Teriflunomide is an oral monotherapy used to treat relapsing multiple sclerosis. Although teriflunomide may be associated with gastrointestinal symptoms, these events are mild and self-limiting. We present a 39-year-old female who developed severe diarrhea and lost 20 pounds within 3 weeks of starting teriflunomide. Despite discontinuing teriflunomide and undergoing cholestyramine washout, her symptoms persisted. Celiac disease on genetic testing was positive, but no anti-transglutaminase and anti-endomysial antibodies were detected. She underwent colonoscopy and biopsy was consistent with lymphocytic colitis. Remission was achieved within days of starting budenoside. Our case describes a rare, but serious, gastrointestinal adverse event of teriflunomide.

Celiac disease and multiple sclerosis in the northwest of Iran

2012 ◽  
Vol 113 (08) ◽  
pp. 495-497
Author(s):  
M. Khoshbaten ◽  
M. Farhoudi ◽  
M. Nikanfar ◽  
H. Ayromlou ◽  
S. Shaafi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Celiac Disease ◽  
Northwest Of Iran

Frequency of celiac disease is not increased among multiple sclerosis patients

2008 ◽  
Vol 14 (5) ◽  
pp. 698-700 ◽  
Author(s):  
A Nicoletti ◽  
F Patti ◽  
S Lo Fermo ◽  
A Sciacca ◽  
P Laisa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Celiac Disease ◽  
Neurological Disorders ◽  
Tissue Transglutaminase ◽  
Specific Antibodies ◽  
Endomysial Antibodies ◽  
Multiple Sclerosis Patients

We evaluated the presence of IgA and IgG celiac disease–related antibodies in a sample of 217 patients with multiple sclerosis (MS) and in a sample of 200 controls not affected by neurological disorders. None of the 217 patients with MS presented IgG and IgA anti-gliadin, anti-endomysial antibodies, anti-tissue transglutaminase and anti-reticulin, whereas only one of the selected controls presented specific antibodies; this subject resulted to be effectively affected by celiac disease. Our data did not show an increased frequency of celiac disease among patients with MS.

Intestinale Dysbiose und Mikrobiomtransfer bei Autoimmunerkrankungen

2021 ◽  
Vol 3 (2) ◽  
pp. 73-74
Author(s):  
Irina Blumenstein
Keyword(s):  
Rheumatoid Arthritis ◽  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Type 1 Diabetes ◽  
Celiac Disease ◽  
Autoimmune Diseases ◽  
Intestinal Microbiome ◽  
Healthy Controls ◽  
Rodent Models

Recent studies have shown that a number of common autoimmune diseases have perturbations of their intestinal microbiome (dysbiosis). These include: Celiac Disease (CeD), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Sjogren’s Syndrome (SS), and Type 1 diabetes (T1D). All of these have intestinal microbiomes that are different from healthy controls. There have been numerous studies using animal models of single probiotics (monoclonal) or mixtures of probiotics (polyclonal) and even complete microbiota transfer (fecal microbial transfer-FMT) to inhibit or delay the onset of autoimmune diseases such as the aforementioned common ones. However, proportionally, fewer clinical trials have utilized monoclonal therapies or FMT than polyclonal therapies for treating autoimmune diseases, even though bacterial mono-therapies do inhibit the development of autoimmune diseases and/or delay the onset of autoimmune diseases in rodent models of those autoimmune diseases. In this review then, we review the previously completed and currently ongoing clinical trials that are testing bacterial therapies (FMT, monoclonal, and polyclonal) to treat common autoimmune diseases and discuss the successes in using bacterial monotherapies to treat rodent models of these common autoimmune diseases.

Sign in / Sign up

Export Citation Format

Share Document